Literature DB >> 11550969

Risk factors associated with thrombosis in patients with antiphospholipid antibodies.

K E Hansen1, D F Kong, K D Moore, T L Ortel.   

Abstract

OBJECTIVE: To define risk factors associated with thrombosis in patients with antiphospholipid antibodies (aPL).
METHODS: Ninety-nine patients with aPL, most of whom had prior thrombosis, were evaluated for the presence of acquired and inherited thrombophilic states. Genomic testing was performed for factor V(R506Q), 3' prothrombin (PTG) and methylene tetrahydrofolate reductase (MTHFR) polymorphisms. Clinical records were reviewed for the presence of acquired risk factors (RF) for thrombosis and events associated with aPL. Univariate statistical analysis was performed using Fisher's exact testing. A neural network statistical model was also used to identify which thrombophilic risk factors were most important in development of arterial and venous thrombosis.
RESULTS: For arterial thrombosis, hypertension, tobacco use, hyperlipidemia, and diabetes mellitus were the most important predictors of thrombosis. By contrast, tobacco use, the 3' PTG and factor V(R506Q) polymorphisms, and previous cardiac surgery were the most important predictors of venous thrombosis.
CONCLUSION: In this hypothesis-generating retrospective study, acquired risk factors were most important in arterial thrombosis, while the presence of factor V(R506Q) and 3' PTG polymorphisms were more important in the development of venous thrombosis. These findings are being validated in an ongoing, prospective study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11550969

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

2.  Antiphospholipid syndrome and recurrent thrombosis--limitations of current treatment strategies.

Authors:  Celia Coelho Henriques; Filipa Lourenço; Begoña Lopéz; António Panarra; Nuno Riso
Journal:  BMJ Case Rep       Date:  2012-03-08

Review 3.  What is antiphospholipid syndrome?

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

Review 4.  Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 5.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.

Authors:  Cassyanne L Aguiar; Doruk Erkan
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

Review 6.  The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome.

Authors:  Reyhan Diz-Kucukkaya; Veysel Sabri Hancer; Bahar Artim-Esen; Yuksel Pekcelen; Murat Inanc
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

Review 7.  Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.

Authors:  Anush Martirosyan; Rustam Aminov; Gayane Manukyan
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

8.  Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  R Kaiser; J L Barton; M Chang; J J Catanese; Y Li; A B Begovich; L A Criswell
Journal:  Genes Immun       Date:  2009-05-07       Impact factor: 2.676

9.  Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature.

Authors:  Alba Jerez-Lienas; Alexis Mathian; Jenifer Aboab; Isabelle Crassard; Miguel Hie; Fleur Cohen-Aubart; Julien Haroche; Denis Wahl; Ricard Cervera; Zahir Amoura
Journal:  Brain Sci       Date:  2021-12-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.